Early Life
Seo Jung-jin was born in Cheongju, South Korea, on October 23, 1957. He graduated from Jemulpo High School and later earned degrees from Konkuk University, including a Bachelor of Industrial Engineering and a Master of Business Administration. His early career included work at Samsung Electronics and as a consultant for Daewoo Motors.
Rise to Success
Seo's career took a pivotal turn in 1999 when he founded Nexol, the predecessor to Celltrion, after the Daewoo Group was dismantled. Recognizing the potential of the then-nascent biosimilar market, he boldly entered the biotech industry. In 2002, he founded Celltrion Inc. His vision led to the development of Remsima, the world's first antibody biosimilar, which gained approval from the U.S. Food and Drug Administration. Under his leadership, Celltrion has generated billions in revenue, with the company generating $1.6 billion in revenue and $440 million in profits in 2020.
Key Business Strategies
Seo's success is attributed to his strategic focus on biosimilars, offering affordable alternatives to expensive brand-name drugs. His leadership has been marked by a willingness to innovate and take calculated risks, including securing funding through unconventional means early in Celltrion's development. Seo retired from Celltrion in March 2021 but returned as chairman in March 2023, demonstrating his continued commitment to the company's growth and vision.
Philanthropy
Seo has demonstrated his commitment to global healthcare by ensuring Celltrion's drugs are accessible to patients in need, including those in Asia.
